Imaging assessment of tumor response: Past, present and future

Future Oncology

Volumn 7, Issue 5, 2011, Pages 669-677

  Afaq, Asim ^a   Akin, Oguz ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

functional cancer imaging; RECIST; tumor response assessment

Indexed keywords

BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE; CYTOSTATIC AGENT;

BONE LESION; BREAST CANCER; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; CYST; DIFFUSION WEIGHTED IMAGING; DRUG CYTOTOXICITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGING; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; PERFUSION IMAGING;

EID: 79956090040     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.38     Document Type: Review

References (61)

1. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47, 207-214 (1981). (Pubitemid 11167383)
2. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J. Natl Cancer Inst. 92, 205-216 (2000). (Pubitemid 30099779)
3. Husband JE, Schwartz LH, Spencer J, et al.: Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br. J. Cancer 90, 2256-2260 (2004). (Pubitemid 38961886)
4. Benjamin RS, Choi H, Macapinlac HA, et al.: We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25, 1760-1764 (2007). (Pubitemid 46797958)
5. Choi H: Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr. Oncol. Rep. 7, 307-311 (2005). (Pubitemid 41149677)
6. Barnacle AM, McHugh K: Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr. Blood Cancer 46, 127-134 (2006). (Pubitemid 43076061)
7. Nowak AK: CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 49(Suppl. 1), S37-S40 (2005).
8. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
9. Bogaerts J, Ford R, Sargent D, et al.: Individual patient data analysis to assess modifications to the RECIST criteria. Eur. J. Cancer 45, 48-60 (2009).
10. Schwartz LH, Bogaerts J, Ford R, et al.: Evaluation of lymph nodes with RECIST 1.1. Eur. J. Cancer 45, 261-267 (2009).
11. Hutchings M, Barrington SF: PET/CT for therapy response assessment in lymphoma. J. Nucl. Med. 50, S21-S30 (2009).
12. Hampson FA, Shaw AS: Response assessment in lymphoma. Clin. Radiol. 63, 125-135 (2008).
13. Kim KW, Lee JM, Choi BI: Assessment of the treatment response of HCC. Abdom. Imaging DOI: 10.1007/s00261-011-9683-3 (2011) (Epub ahead of print).
14. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60 (2010).
15. Choi SH, Moon WK: Contrast-enhanced MR imaging of lymph nodes in cancer patients. Korean J. Radiol. 11, 383-394 (2010).
16. Nishino M, Jagannathan JP, Ramaiya N, et al.: Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am. J. Roentgenol. 195, 281-289 (2010).
17. Weber WA: Assessing tumor response to therapy. J. Nucl. Med. 50(Suppl. 1), S1-S10 (2009).
18. Zee YK, OConnor JP, Parker GJ, et al.: Imaging angiogenesis of genitourinary tumors. Nat. Rev. Urol. 7, 69-82 (2010).
19. Choi H, Charnsangavej C, de Castro Faria S, et al.: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am. J. Roentgenol. 183, 1619-1628 (2004). (Pubitemid 44210530)
20. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al.: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br. J. Cancer 102, 803-809 (2010).
21. Gill RR, Gerbaudo VH, Sugarbaker DJ, et al.: Current trends in radiologic management of malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21, 111-120 (2009).
22. Choi H: Response evaluation of gastrointestinal stromal tumors. Oncologist 13, 4-7 (2008).
23. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al.: Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol. 5, 95-112 (2010).
24. Smith AD, Lieber ML, Shah SN: Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Am. J. Roentgenol. 194, 157-165 (2010).
25. Dudeck O, Zeile M, Reichardt P, Pink D: Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann. Oncol. DOI: 10.1093/annonc/mdq696 (2011) (Epub ahead of print).
26. Eradat J, Abtin F, Gutierrez A, Suh R: Evaluation of treatment response after nonoperative therapy for early-stage non-small cell lung carcinoma. Cancer J. 17, 38-48 (2011).
27. Lee HY, Lee KS, Ahn MJ, et al.: New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer DOI:10.1016/j.lungcan.2010.10.019 (2010) (Epub ahead of print).
28. Lee HY, Lee KS, Hwang HS, et al.: Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J. Radiol. 11, 618-626 (2010).
29. Padhani AR, Khan AA: Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol. 5, 39-52 (2010).
30. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B: Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. Am. J. Roentgenol. 193, 1044-1052 (2009).
31. González Hernando C, Esteban L, Caas T, et al.: The role of magnetic resonance imaging in oncology. Clin. Transl. Oncol. 12, 606-613 (2010).
32. Fernández-Guinea O, Andicoechea A, González LO, et al.: Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer. BMC Cancer 10, 8 (2010).
33. Matsuoka S, Hunsaker AR, Gill RR, et al.: Functional MR imaging of the lung. Magn. Reson. Imaging Clin. N. Am. 16, 275-289 (2008). (Pubitemid 351636233)
34. Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO: Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br. J. Cancer 102, 1-7 (2010).
35. Dhermain FG, Hau P, Lanfermann H, et al.: Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 9, 906-920. (2010).
36. Glunde K, Bhujwalla ZM: Metabolic tumor imaging using magnetic resonance spectroscopy. Semin. Oncol. 38, 26-41 (2011).
37. Koh DM, Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 188, 1622-1635 (2007). (Pubitemid 46866868)
38. Arlinghaus LR, Li X, Levy M, et al.: Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J. Oncol. (2010) PII: 919620. (2010).
39. Afaq A, Andreou A, Koh DM: Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging 10, S179-S88 (2010).
40. Fenchel M, Konaktchieva M, Weisel K, et al.: Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study. Acad. Radiol. 17, 1326-1333 (2010).
41. Koh DM, Blackledge M, Collins DJ, et al.: Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre Phase I clinical trial. Eur. Radiol. 19, 2728-2738 (2009).
42. Jain R: Perfusion CT imaging of brain tumors: an overview. Am. J. Neuroradiol. DOI 10.3174/ ajnr.A2263 (2010) (Epub ahead of print).
43. Pollard RE, Larson RF: Dynamic contrast-enhanced computed tomography for the quantification of tumor response to vasoactive agents in a rat tumor model: preliminary results. Contrast Media Mol. Imaging 6(1), 28-34 (2011).
44. Choi SH, Chung JW, Kim HC, et al.: The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest. Radiol. 45, 427-436 (2010).
45. Hegenscheid K, Behrendt N, Rosenberg C, et al.: Assessing early vascular changes and treatment response after laser-induced thermotherapy of pulmonary metastases with perfusion CT: initial experience. Am. J. Roentgenol. 194, 1116-1123 (2010).
46. Squillaci E, Manenti G, Cicciò C, et al.: Perfusion-CT monitoring of cryo-ablated renal cells tumors. J. Exp. Clin. Cancer Res. 28, 138 (2009).
47. Wu GY, Ghimire P: Perfusion computed tomography in colorectal cancer: protocols, clinical applications and emerging trends. World J. Gastroenterol. 15, 3228-3231 (2009).
48. Goh V, Dattani M, Farwell J, et al.: Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. Eur. Radiol. 21(5), 974-981 (2010).
49. Bellomi M, Viotti S, Preda L, DAndrea G, Bonello L, Petralia G: Perfusion CT in solid body-tumours. Part II: clinical applications and future development. Radiol. Med. 115, 858-874 (2010).
50. Kong WT, Zhang WW, Guo HQ, et al.: Application of contrast-enhanced ultrasonography after radiofrequency ablation for renal cell carcinoma: is it sufficient for assessment of therapeutic response? Abdom. Imaging DOI: 10.1007/ s00261-010-9665-x (2010) (Epub ahead of print).
51. Lassau N, Koscielny S, Chami L, et al.: Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification - preliminary results. Radiology 258(1), 291-300 (2011).
52. Lassau N, Chami L, Koscielny S, et al.: Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest. New Drugs DOI: 10.1007/ s10637-010-9592-2 (2010) (Epub ahead of print).
53. Lassau N, Koscielny S, Albiges L, et al.: Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin. Cancer Res. 16, 1216-1225 (2010).
54. Lassau N, Chami L, Chebil M, et al.: Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov. Med. 11, 18-24 (2011).
55. Wahl RL, Jacene H, Kasamon Y, et al.: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, S122-S150 (2009).
56. Zaidi H, Montandon ML, Alavi A: The clinical role of fusion imaging using PET, CT, and MR imaging. Magn. Reson. Imaging Clin. N. Am. 18, 133-149 (2010).
57. Marten K, Auer F, Schmidt S, Kohl G, Rummey EJ, Engelke C: Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur. Radiol. 16, 781-790 (2006). (Pubitemid 43380236)
58. Keil S, Behrendt FF, Stanzel S, et al.: Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semiautomated and manual measurement of RECIST and WHO criteria. Eur. Radiol. 18, 2456-2465 (2008).
59. Fabel M, von Tengg-Kobligk H, Giesel FL, et al.: Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV - a feasibility study. Eur. Radiol 18, 1114-1122 (2008).
60. Ertl-Wagner BB, Blume JD, Peck D, et al.: Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 trial. Eur. Radiol 19, 599-609 (2009).
61. van Persijn van Meerten EL, Gelderblom H, Bloem JL: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur. Radiol. 20, 1456-1467 (2010).